Key result
Mineralocorticoid receptor antagonists and sodium-glucose co-transporter 2 inhibitors may have synergistic beneficial effects on cardiovascular outcomes in heart failure.
Why the study?
Does the combination of MRA and SGLT2i improve cardiovascular outcomes in patients with heart failure?
Does the combination of MRA and SGLT2i improve cardiovascular outcomes in patients with heart failure?
The combination of SGLT2 inhibitors and MRAs may provide synergistic cardiovascular benefits in the management of heart failure.
Potential MRA-SGLT2i synergy in HF is hypothesis-generating; leaves open confirmation in outcome trials.
Synergistic effects of MRA and SGLT2i in HF: Key beneficial effects (+) of mineralocorticoid receptor antagonists (MRA) and sodium–glucose co-transporter inhibitors (SGLT2i) on relevant cardiovascular outcomes in heart failure (HF) as well as potential synergism. Potential typical adverse effects (−) are also shown. CV, cardiovascular, DKD, diabetic kidney disease; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; LV, left ventricular; MRA, mineralocorticoid receptor antagonists; T2DM, type 2 diabetes mellitus; SGLT2i, sodium–glucose co-transporter inhibitors
No takes yet. Share an insight, caveat, or question.
Bauersachs et al. (2023) conducted a review in Heart failure. Mineralocorticoid receptor antagonists (MRA) and sodium-glucose co-transporter 2 inhibitors (SGLT2i) was evaluated. Mineralocorticoid receptor antagonists and sodium-glucose co-transporter 2 inhibitors may have synergistic beneficial effects on cardiovascular outcomes in heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: